Charles River Laboratories International (Charles River Laboratories International) Interest Expense : $-137 Mil (TTM As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Charles River Laboratories International Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Charles River Laboratories International's interest expense for the three months ended in Mar. 2024 was $ -35 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-137 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Charles River Laboratories International's Operating Income for the three months ended in Mar. 2024 was $ 126 Mil. Charles River Laboratories International's Interest Expense for the three months ended in Mar. 2024 was $ -35 Mil. Charles River Laboratories International's Interest Coverage for the quarter that ended in Mar. 2024 was 3.60. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Charles River Laboratories International Interest Expense Historical Data

The historical data trend for Charles River Laboratories International's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Charles River Laboratories International Interest Expense Chart

Charles River Laboratories International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-60.88

-86.43

-73.91

-59.29

-136.71

Charles River Laboratories International Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-34.38	-35.04	-33.74	-33.54	-35.00

Charles River Laboratories International Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-137 Mil.

Charles River Laboratories International (NYSE:CRL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Charles River Laboratories International's Interest Expense for the three months ended in Mar. 2024 was $-35 Mil. Its Operating Income for the three months ended in Mar. 2024 was $126 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $3,079 Mil.

Charles River Laboratories International's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	125.977	/	-35.001
	=	3.60

The higher the ratio, the stronger the company's financial strength is.

Charles River Laboratories International (Charles River Laboratories International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Charles River Laboratories International Inc (NYSE:CRL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

CRL:Mexico RV6:Germany

Address

251 Ballardvale Street, Wilmington, MA, USA, 01887

Website

https://www.criver.com

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Executives

Victoria L Creamer	officer: EVP & Chief People Officer	164 PINE HILL ROAD, NEW FAIRFIELD CT 06812
Joseph W Laplume	officer: EVP, Corp Strategy & Develop	251 BALLARDVALE STREET, WILMINGTON MA 01887
Birgit Girshick	officer: Corporate Executive VP	251 BALLARDVALE STREET, WILMINGTON MA 01887
James C Foster	director, officer: President and CEO	251 BALLARDVALE ST, WILMINGTON MA 01887
Richard F Wallman	director	HONEYWELL, 101 COLUMBIA ROAD, MORRISTOWN NJ 07962
William D Barbo	officer: Corporate Executive VP & CCO	251 BALLARDVALE STREET, WILMINGTON MA 01887
Michael Gunnar Knell	officer: CSVP&Chief Accounting Officer	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
George Massaro	director
Shannon M Parisotto	officer: CEVP, Disc & Safety Assessment	251 BALLARDVALE ST, WILMINGTON MA 01887
Flavia Pease	officer: Corporate Executive VP	251 BALLARDVALE STREET, WILMINGTON MA 01887
David Ross Smith	officer: Corporate Executive VP & CFO	251 BALLARDVALE STREET, WILMINGTON MA 01887
Deborah Turner Kochevar	director	251 BALLARDVALE STREET, WILMINGTON MA 01887
Milne George M Jr	director
Stephen D Chubb	director	C/O MATRITECH INC, 330 NEVADA STREET, NEWTON MA 02460
George Llado	director	251 BALLARDVALE STREET, WILMINGTON MA 01887